Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
Gender and the hygiene hypothesis.
Neurodegeneration: From Multiple Sclerosis to Alzheimer’s Disease
Summit 2013 + Expo
Long-Term Effects of Exposure to Disease-Modifying Drugs in the Offspring of Mothers with Multiple Sclerosis: A Retrospective Chart Review.
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System.
Immunopathogenesis of neuromyelitis optica.
An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis.
MS Research Roundup: January 29, 2014
HLA-DRB1*15:01 and multiple sclerosis: a female association?
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis.
Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
Sex ratio of multiple sclerosis and clinical phenotype.
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
T(H)17 cytokines in autoimmune neuro-inflammation.
Episode 56 with Dr. Gavin Giovannoni, on early phase 3 results of ocrelizumab, the first experimental drug to show some benefit in a progressive form of multiple sclerosis in a major trial
Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta™ for RRMS
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-Related Hospitalizations: Integrated Analysis of the Delayed-Release Dimethyl Fumarate Phase III Studies.
Episode 38 with Dr. Joseph Berger on progressive multifocal leukoencephalopathy
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Blood Brain Barrier Meeting

Pages